Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Allergy, Asthma & Clinical Immunology
Published in: Allergy, Asthma & Clinical Immunology 2/2014

Open Access 01-12-2014 | Meeting abstract

Proteinase-activated receptor-2 (PAR-2) expression on inflammatory cells in severe asthma

Authors: Drew Nahirney, Nami Shrestha Palikhe, Cheryl Laratta, Vivek Gandhi, Dilini Vethanayagam, Mohit Bhutani, Irvin Mayers, Lisa Cameron, Harissios Vliagoftis

Published in: Allergy, Asthma & Clinical Immunology | Special Issue 2/2014

Login to get access

Excerpt

PAR-2, a G-coupled receptor activated by serine proteinases, is widely expressed in the human body and is involved in inflammation. We have shown that PAR-2 activation in the airways plays a pathogenetic role in mouse models of asthma. PAR-2 expression is increased in the epithelium of asthmatic subjects, but its expression on immune and inflammatory cells of asthmatic individuals has not been. Severe asthma has different phenotypic characteristics from mild-moderate disease. In this study we compared PAR-2 expression on immune cells between subjects with mild/moderate and severe asthma. …
Metadata
Title
Proteinase-activated receptor-2 (PAR-2) expression on inflammatory cells in severe asthma
Authors
Drew Nahirney
Nami Shrestha Palikhe
Cheryl Laratta
Vivek Gandhi
Dilini Vethanayagam
Mohit Bhutani
Irvin Mayers
Lisa Cameron
Harissios Vliagoftis
Publication date
01-12-2014
Publisher
BioMed Central
DOI
https://doi.org/10.1186/1710-1492-10-S2-A50

Other articles of this Special Issue 2/2014

Allergy, Asthma & Clinical Immunology 2/2014 Go to the issue

Meeting abstract

The efficacy and safety of the short ragweed sublingual immunotherapy tablet MK-3641 is similar in asthmatic and nonasthmatic subjects treated for allergic rhinitis with/without conjunctivitis

Meeting abstract

A pilot study of quality of life, mood, sleepiness and fatigue in patients with primary humoral immunodeficiency transitioning to subcutaneous immunoglobulin therapy

Meeting abstract

The Allergic Rhinitis - Clinical Investigator Collaborative (AR-CIC) - optimizing the Nasal Allergen Challenge (NAC) model

Meeting abstract

Magnitude of changes in patient symptom and medication scores in grass allergy immunotherapy trials: dependency on levels of pollen exposure

Meeting abstract

Tobacco smoke induces changes in IL-1 family in bronchial epithelial cells obtained from asthmatic individuals

Meeting abstract

Technical evaluation of an allergen Challenge TheatreTM